more_reports

Ardelyx Inc.

ARDX:NASDAQ

Ardelyx is focused on enhancing the lives of people with cardiorenal diseases by developing first-in-class medicines that matter. Ardelyx's cardiorenal pipeline includes the Phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with CKD on dialysis, and RDX013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease.

streetwise book logo Streetwise Company Fact Sheet

2024/7/14 16:27:37

(ARDX:NASDAQ)